Briquilimab is a monoclonal antibody commercialized by Jasper Therapeutics, with a leading Phase II program in Severe Combined Immune Deficiency (SCID).

Ligelizumab is a monoclonal antibody commercialized by Novartis, with a leading Phase III program in Food Allergy.

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of Pittsburgh study ...

A new approach to treat rosacea and other inflammatory skin conditions could be on the horizon, according to a University of ...

About half of people with "chronic spontaneous urticaria," or CSU, the most common type of chronic hives, experience what ...

"Medical Journeys" chart a path each step of the way for physicians and patients and provide continual resources and support, ...

MCLEAN, VA / ACCESSWIRE / December 10, 2024 / Dr. Amir Bajoghli and his colleagues have recently published an insightful case ...

Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of ...

South Korean biopharmaceutical firm Celltrion said Monday that it has received approval from Health Canada for Omlyclo, its omalizumab biosimilar referencing Xolair, designed to treat allergic asthma ...

BMO Capital analyst Etzer Darout initiated coverage of Jasper Therapeutics (JSPR) with an Outperform rating and $63 price target Jasper is a ...